Home
TARA
TARA News

Latest Protara Therapeutics Inc. (TARA) News on May 11, 2025

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

3 days ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 days ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

GlobeNewswire

15 days ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

GlobeNewswire

18 days ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

GlobeNewswire

a month ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

GlobeNewswire

a month ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

GlobeNewswire

2 months ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

2 months ago

Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire

2 months ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

3 months ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

3 months ago

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Protara Highlights Recent Updates and Anticipated 2025 Milestones

GlobeNewswire

4 months ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Protara Announces Closing of $100 Million Public Offering

GlobeNewswire

5 months ago

Protara Announces Closing of $100 Million Public Offering

Protara Announces Pricing of $100 Million Public Offering

GlobeNewswire

5 months ago

Protara Announces Pricing of $100 Million Public Offering

Protara Announces Proposed Public Offering

GlobeNewswire

5 months ago

Protara Announces Proposed Public Offering

Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most

Simply Wall St.

5 months ago

Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

GlobeNewswire

5 months ago

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

GlobeNewswire

5 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

GlobeNewswire

6 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

6 months ago

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

GlobeNewswire

6 months ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

GlobeNewswire

7 months ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

GlobeNewswire

8 months ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

GlobeNewswire

8 months ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

8 months ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Simply Wall St.

9 months ago

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

9 months ago

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

GlobeNewswire

a year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

GlobeNewswire

a year ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

GlobeNewswire

a year ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

GlobeNewswire

a year ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

a year ago

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

Red Cat Continues Global Expansion Efforts with Introduction to Middle East Market

GlobeNewswire

a year ago

Red Cat Continues Global Expansion Efforts with Introduction to Middle East Market

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

GlobeNewswire

a year ago

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

ACCESSWIRE

a year ago

ARIA Cybersecurity Calls for New Approach to Securing Operational Technology from Sophisticated Cyberattacks

Protara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

Gamida Cell Actively Pursuing Strategic Alternatives

GlobeNewswire

a year ago

Gamida Cell Actively Pursuing Strategic Alternatives

Globus Maritime Limited Announces the Delivery of a 2024-Built Ultramax Dry Bulk Vessel “Glbs Hero,” Expanding Fleet to Seven Vessels

GlobeNewswire

a year ago

Globus Maritime Limited Announces the Delivery of a 2024-Built Ultramax Dry Bulk Vessel “Glbs Hero,” Expanding Fleet to Seven Vessels

Spectaire Signs Agreement to Expand into Brazil - a Country with Over 2 Million Heavy Duty Diesel Trucks Operating

PR Newswire

a year ago

Spectaire Signs Agreement to Expand into Brazil - a Country with Over 2 Million Heavy Duty Diesel Trucks Operating

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

PR Newswire

a year ago

SPECTAIRE ANNOUNCES THE COMPLETION OF THE FORWARD PURCHASE AGREEMENT WITH METEORA FUNDS

A Look At The Fair Value Of CSP Inc. (NASDAQ:CSPI)

Simply Wall St.

a year ago

A Look At The Fair Value Of CSP Inc. (NASDAQ:CSPI)

Velo3D to Present at the 26th Annual Needham Growth Conference

Business Wire

a year ago

Velo3D to Present at the 26th Annual Needham Growth Conference

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

Pixie Dust Technologies, Inc. Introduces Additional Pricing Option for Proprietary Speaker kikippa

PR Newswire

a year ago

Pixie Dust Technologies, Inc. Introduces Additional Pricing Option for Proprietary Speaker kikippa

GlobeNewswire

a year ago

Abits Group Regains Compliance with NASDAQ Minimum Bid Price Requirement

Movano Health and ams OSRAM Collaborate to Deliver Accurate Lifestyle Monitoring Solutions for Women

PR Newswire

a year ago

Movano Health and ams OSRAM Collaborate to Deliver Accurate Lifestyle Monitoring Solutions for Women

SurgePays Acquires ClearLine Mobile

GlobeNewswire

a year ago

SurgePays Acquires ClearLine Mobile

enVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability

Simply Wall St.

a year ago

enVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Business Wire

a year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Bull Of The Day: Stronghold Digital Mining (SDIG)

Zacks

a year ago

Bull Of The Day: Stronghold Digital Mining (SDIG)

FLANIGAN'S REPORTS EARNINGS

PR Newswire

a year ago

FLANIGAN'S REPORTS EARNINGS

Business Wire

a year ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?

Simply Wall St.

a year ago

Can Mixed Fundamentals Have A Negative Impact on AstroNova, Inc. (NASDAQ:ALOT) Current Share Price Momentum?

Companies Like Paltalk (NASDAQ:PALT) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like Paltalk (NASDAQ:PALT) Are In A Position To Invest In Growth

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook

Simply Wall St.

a year ago

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook

Business Wire

a year ago

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Reuters

a year ago

UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy

Reuters

a year ago

US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

GlobeNewswire

a year ago

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

GlobeNewswire

a year ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

Business Wire

a year ago

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

InvestorPlace

a year ago

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

Epsilon Energy (NASDAQ:EPSN) Is Paying Out A Dividend Of $0.0625

Simply Wall St.

a year ago

Epsilon Energy (NASDAQ:EPSN) Is Paying Out A Dividend Of $0.0625

GlobeNewswire

a year ago

Garden Stage Limited Announces Closing of Initial Public Offering

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

GlobeNewswire

a year ago

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

GlobeNewswire

a year ago

Garden Stage Limited Announces Pricing of Initial Public Offering

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

GlobeNewswire

a year ago

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant

ACCESSWIRE

a year ago

Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant

PR Newswire

a year ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

PR Newswire

a year ago

BIT Mining Limited Announces Unaudited Financial Results for the Third Quarter ended September 30, 2023

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

GlobeNewswire

a year ago

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Business Wire

a year ago

BlackRock Enhanced Government Fund, Inc. Completes Annual Repurchase Offer

Business Wire

a year ago

BlackRock Enhanced Government Fund, Inc. Announces Expiration of Annual Repurchase Offer

DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2m

Simply Wall St.

a year ago

DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2m

REPLAY: Join CEO of Live Ventures in Fireside Chat

CorpGov.com

a year ago

REPLAY: Join CEO of Live Ventures in Fireside Chat

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

PR Newswire

a year ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) Soars 27% But It's A Story Of Risk Vs Reward

Simply Wall St.

a year ago

Jianzhi Education Technology Group Company Limited (NASDAQ:JZ) Soars 27% But It's A Story Of Risk Vs Reward

BIT Mining Limited to Report Third Quarter 2023 Financial Results on November 17, 2023

PR Newswire

2 years ago

BIT Mining Limited to Report Third Quarter 2023 Financial Results on November 17, 2023

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

RADCOM Ltd. (NASDAQ:RDCM) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

RADCOM Ltd. (NASDAQ:RDCM) Q3 2023 Earnings Call Transcript

Tandy Leather Factory Reports Third Quarter 2023 Results

GlobeNewswire

2 years ago

Tandy Leather Factory Reports Third Quarter 2023 Results

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript

3 Tech Stocks That Wall Street Loves More Than Nvidia

InvestorPlace

2 years ago

3 Tech Stocks That Wall Street Loves More Than Nvidia

Share on Social Networks: